↓ Skip to main content

Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study

Overview of attention for article published in BMC Nephrology, February 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
2 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study
Published in
BMC Nephrology, February 2015
DOI 10.1186/s12882-015-0006-8
Pubmed ID
Authors

Piergiorgio Messa, Mario Cozzolino, Diego Brancaccio, Giuseppe Cannella, Fabio Malberti, Anna Maria Costanzo, Umberto di Luzio Paparatti, Vincenzo Festa, Giuliana Gualberti, Sandro Mazzaferro

Abstract

Mortality rate among patients with stage five chronic kidney disease (CKD) maintained on hemodialysis (HD) is high. Although evidence suggests that use of Vitamin D Receptor Activators (VDRA) in CKD patients increases survival, few studies have examined the effect of VDRA in incident HD patients. The FARO-2 study evaluated the clinical outcome of VDRA therapy on mortality in incident HD patients. FARO-2 was a longitudinal epidemiological study performed on 568 incident HD patients followed prospectively from 26 dialysis centers over a 3-year period. Data were collected every 6 months using a questionnaire, obtaining clinical, biochemical and therapeutic parameters. Kaplan-Meier curves and Cox proportional hazard regression models were used to determine cumulative probability of time-to-death and adjusted hazard ratios. 568 patients (68% male) with an average age of 65.5 years were followed up. Mean dialysis duration at study entry was 3 months. VDRA use increased from 46% at 6 months to 54.7% at 36 months of follow-up (p = 0.08). No difference was observed in the presence of comorbid diseases at baseline in patients with and without VDRA therapy. Cumulative probability of survival at 24 months was 74.5% (95% CI: 70.2-78.3). Patients receiving VDRA therapy showed a significant increase in survival at 24 months (80.7%; 95% CI: 75.7-84.8) compared to those without (63.3%; 95% CI: 54.8-70.7, p <0.01). The presence of vascular disease, decreased hemoglobin, increased P and lack of VDRA treatment were significantly associated with an increased risk of mortality. Lack of VDRA treatment still remained significant as a predictor of mortality after adjusting for levels of PTH, P and Ca (HR = 2.16, 95% CI: 1.09-4.30, p = 0.03). Findings from FARO-2 indicate that in incident HD patients VDRA therapy was associated with increased survival.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 16%
Student > Bachelor 5 16%
Researcher 4 13%
Student > Doctoral Student 3 9%
Other 3 9%
Other 8 25%
Unknown 4 13%
Readers by discipline Count As %
Medicine and Dentistry 17 53%
Nursing and Health Professions 2 6%
Agricultural and Biological Sciences 1 3%
Psychology 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 4 13%
Unknown 6 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2016.
All research outputs
#7,459,450
of 12,373,620 outputs
Outputs from BMC Nephrology
#594
of 1,235 outputs
Outputs of similar age
#116,650
of 237,348 outputs
Outputs of similar age from BMC Nephrology
#3
of 7 outputs
Altmetric has tracked 12,373,620 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,235 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 237,348 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.